It is used for the treatment of schizophrenia and schizoaffective disorder.<unk>  palmitate long-acting injection compared to risperidone for schizophrenia When flexibly dosed every four weeks,<unk>  palmitate appears comparable in efficacy and tolerability to risperidone. In short-term studies,<unk>  palmitate – the longer-acting injection – has a similar adverse effect profile to related compounds such as risperidone by mouth. No difference was found in the high rate of reported adverse sexual outcomes and<unk>  palmitate is associated with an increase in serum prolactin. Outcome Findings in words Findings in numbers Quality of evidence Global state: No clinically important change No 30% improvement on PANSS score.Follow-up: 13-53 weeks There is no clear difference between people given<unk>  palmitate and those receiving risperidone for this outcome. These findings are based on data of low quality. RR 1.03 (0.93 to 1.14) Low Relapse Recurrence of psychotic symptoms.Follow up: 13-53 weeks There is no clear difference between people given<unk>  palmitate and those receiving risperidone for the outcome of 'relapse'. Data supporting this finding are based on moderate quality evidence. RR 1.23 (0.98 to 1.53) Moderate Leaving the study early - For any reason.Follow up: 13-53 weeks<unk>  palmitate causes little or no increase to the chance of leaving the study. RR 1.12 (1 to 1.25) High - Because of lack of efficacy.Follow up: 13-53 weeks<unk>  palmitate may increase the risk of finding treatment unacceptable or being withdrawn from treatment outcome for the reason of perceived lack of efficacy compared with risperidone. Data are based on moderate quality evidence. RR 1.35 (1.06 to 1.71) Moderate Adverse event: death Follow up: 13-53 weeks There was no clear difference between people given<unk>  palmitate and those receiving risperidone for this rare outcome. These findings are based on data of low quality. RR 3.62 (0.6 to 21.89) Low Missing outcomes Outcomes of 'cost' and 'quality of life' are not reported in the included randomized trials.
Paliperidone
Chlortalidone
Domperidone
Primidone
Ziprasidone
Fluparoxan
Rimonabant
Loprazolam